Joe Colucci: All Related Content

All related content for this individual is listed below.

"What are the benefits?' What are the risks? Are there alternatives?"

  • By
  • Joe Colucci
May 11, 2012
Publication Image

Those are the final questions in this article on Yahoo! News, under the title "How Much Medicine Do You Need?" The final quote comes from Rita Redberg, editor of the medical journal Archives of Internal Medicine, and pretty much sums up the questions that people ought to ask themselves when considering treatment. There's a lot more in the article that we're not going to summarize--check it out!

Issues:

The Lifesaving(?) Technology of Facebook

  • By
  • Shannon Brownlee
  • Joe Colucci
May 10, 2012
Publication Image

When most of us think about Facebook, the first phrase that comes to mind probably isn’t “good Samaritan.”  Facebook is an easy way to keep in touch with friends, and it can be a gigantic time-suck, for sure, but last week the site did something that could truly benefit a lot of people. On May 1, Facebook launched an initiative to encourage users to become organ donors, and within 24 hours there had been a spike in the number of people volunteering their body parts for the good of others. California’s registry saw almost two months’ worth of people sign up within the first day after the Facebook put up the feature.

Organ transplantation is one of the miracles of modern medicine, but there simply aren’t enough organs to go around for all the patients who need them. According to the United Network for Organ Sharing (UNOS), there are 72,900 people on active lists waiting for an organ. Compare that number to the 2,263 transplants that took place between January 2011 - 2012. Last year, more than 6,000 people died waiting for an organ.Obviously, increasing the number of organ donors could have a huge impact on the number of transplants – and on the lives of thousands of people.

Why don’t more people become donors? Some object on religious grounds, but the biggest obstacle is inertia. Most of us who sign up to be organ donors (I’m one of them) do so when we renew our driver’s license, by checking a box on a form saying we want to donate our organs. If you don’t mark the form, it’s assumed you don’t want to donate. Most people only encounter this choice every few years, when their driver’s license is up for renewal, and it’s hard to think about such a decision while standing at a Department of Motor Vehicles counter.

Some countries, such as Spain, Australia and Germany, have opt-out systems. It’s assumed that you are willing to donate unless you’ve said you prefer not to. Rates of donation in those countries are sometimes higher than in the US, although some presumed-consent countries have much lower rates. (Factors other than the number of donors, like the availability of surgical facilities and transplant surgeons, can affect the number of actual transplants in different countries.)

Another way to get more people to donate would be a “mandated choice.” This idea was proposed by behavioral economist Richard Thaler, in his book Nudge: Improving Decisions About Health, Wealth, and Happiness (with Cass Sunstein). Instead of a form that you can simply leave empty if you don’t know whether you want to donate, you have to choose between “yes” and “no.” There’s psychological evidence that even having to make that choice could get more people to think about their preferences and choose to donate. Israel has yet another incentive to get people to donate: those who are registered as donors get priority if they later need an organ themselves. Facebook’s effort depends on another psychological effect, the power of social persuasion. If your friends are all donors, maybe you should sign up, too.

Whether or not Facebook’s initiative will have a sustained effect on the number of available organs remains to be seen, but there’s a side to this issue that deserves at least a mention. Organ transplants are expensive. The surgery itself can cost as much as a million dollars, and that’s not including the drugs and other care transplant patients require for the rest of their lives. Granted, that’s money well spent in terms of lives saved. But imagine if there were enough organs for every person who needed one. We’d have to find more than $100 billion a year in addition to what we’re already paying for health care.

I’m not suggesting more organ donation is a bad idea, or that we shouldn’t do more transplants. Just the opposite. It would be money well spent. It’s also yet another reason to weed out the trillions of dollars we are on track to waste over the next decade on health care that doesn’t help patients or improve lives.

Issues:

A Belated SCOTUS Wrap-up, and A Look Forward

  • By
  • Joe Colucci
April 13, 2012
Publication Image

Unless you've been living under a whole pile of rocks, you heard about the Supreme Court’s oral arguments in Florida v. Department of Health and Human Services—the Obamacare case. You’ve probably heard by now from a dozen reporters and pundits who claim that they know which way the Court will rule.

I’m not going to make that claim. There are understandable arguments on both sides, and it’s incredibly difficult to predict how this Court will decide on such an important, divisive, politically charged issue.

Instead, I want to provide a little perspective. Even if the Court decides that the individual mandate is not a Constitutional exercise of Congressional power, the consensus of Courtwatchers is that they’re unlikely to toss the entire law down the drain with it. If the mandate is unconstitutional, there are two main options without throwing out the whole thing: the mandate might get thrown out on its own, or two crucial insurance reforms (community rating and guaranteed issue) might go with it.

Guaranteed issue and community rating are the key pieces of the law—they require insurers to give insurance to anyone who comes asking, and limit the amount that prices can vary between people, respectively. The individual mandate was designed by the Heritage Foundation during the last health care debate (over President Clinton’s health care reforms, in 1993), and it's designed to attack two economic problems that can emerge when people have that protection: moral hazard and the insurance “death spiral.” Moral hazard is the economics term for the danger that healthy people might go without insurance, only to buy it (at the low, community-rated price) if they get sick. If people can do that, insurance costs have to be higher for responsible buyers who get in at the beginning. The “death spiral” is a similar phenomenon, where people who buy insurance are sicker than average, which drives up the price of insurance. That price increase makes more healthy people drop their coverage, leading to an even sicker risk pool and higher costs. Eventually, the insurance market falls apart because the only people left wanting to buy insurance are too sick to afford their own health care costs.

The mandate works by pushing healthy people to buy insurance even when they’re likely to stay healthy—thereby preventing moral hazard, and avoiding death spirals. The thing is, any policy mechanism that makes going without insurance less appealing will work the same way. That means even if Congress isn’t allowed to create an individual mandate, there are a whole slew of other options for what they could do. Several mechanisms have been proposed that would achieve exactly the same result as the mandate penalty, but would do it through the tax code, where Congressional power is less restricted. Those might still be challenged in court, but would have a better chance of survival. Alternatively, Congress could just force people who choose to go without insurance to stay that way, even if they get sick: it would be entirely within Congress’s power to say that an individual who could have gotten insurance and didn’t, would: 1) not be eligible for insurance subsidies if he wanted to get insurance on the exchanges; 2) not have guaranteed coverage for any pre-existing condition; 3) not be protected by guaranteed issue and community rating, so he might have to pay an incredibly high premium if he could get insurance at all. Those penalties might be in effect for five years from the date when he declined insurance, in order to strongly discourage people from making rash choices because they feel healthy this month.

That would, in effect, create a universal insurance system, with an opt-out for the very confident and those who genuinely wish to self-insure. It would be indisputably within Congress’s Commerce Clause power, too—it would be a direct regulation of insurers and participants in the insurance market. If the mandate gets struck down, it would be a relatively simple legislative task (although perhaps a heavy political lift) to fix the law and restore its universality.

As an eternal reminder: the Affordable Care Act didn’t fix the American health care system—it aimed only at the health insurance system. Researchers have documented unnecessary care that costs hundreds of billions of dollars each year, and the law does little to attack that waste. Correcting the delivery system will require hard political and practical conversations about global budgets, evidence-based care, and getting control of the outrageous growth in health care resources. Depending on how the Court rules, health care might fall off the political radar this year, but you can be sure it’ll be back soon enough. The system has too much waste—and too much opportunity for improvement—to let it go when the Justices rule.

Unnecessary Care on the Diane Rehm Show

  • By
  • Joe Colucci
April 9, 2012
Diane Rehm Show logo

If you missed the broadcast (and our live-tweeting!) this morning, be sure to check out the great discussion of Choosing Wisely, unnecessary care, and what patients and providers can do about it on the Diane Rehm show this morning! The panel included our program director, Shannon Brownlee, Dr Christine Cassel of the ABIM Foundation, Dr. Eric Topol of Scripps Health, and Dr. Ranit Mishori of the Georgetown University School of Medicine.

The panel was well-informed and willing to admit the strengths and weaknesses of the Choosing Wisely program. They all agreed that patients can't fix overtreatment on their own--doctors have to take responsibility for making evidence-based recommendations, and for considering whether test results have any real clinical consequences. In cases where a test doesn't provide any useful or consequential information, the responsible thing to do is skip the test. They also agreed that the problem goes beyond fear of malpractice lawsuits--overtreatment and unnecessary care comes from a culture of "more medical care is better," and the financial incentives that go along with that assumption.

There's a lot more in the program: check it out! And don't forget to look at the website for the Avoiding Avoidable Care conference, coming up later this month!

A good start, but only a start

  • By
  • Joe Colucci
April 5, 2012
Publication Image

Yesterday, the ABIM Foundation's Choosing Wisely initiative released a list of 45 medical procedures in nine specialties that doctors shouldn't use, and that patients should know are not necessary. The procedures include a variety of treatments, screening tests, and diagnostic tests, including: MRI and CT scans for low back pain without red flags; cardiac imaging tests for patients with chest pain and low risk of complications; brain imaging for a simple headache; and curative treatment for cancer patients when there's no reason to think the treatments will work.  All of the recommendations are based on solid medical evidence that the procedures harm patients, provide no benefit, or provide extremely small benefits at very high costs.

It's remarkable that the ABIM Foundation was able to pull together panels of people in all of these specialties (allergy, asthma, and immunology, family medicine, cardiology, general internal medicine, radiology, gastroenterology, clinical oncology,  nephrology, and nuclear cardiology) who were willing to agree that these treatments and tests are not beneficial to patients. It speaks to the strength of the evidence against performing useless treatments.

Dr. Vikas Saini, a cardiologist and president of the Lown Cardiovascular Research Foundation, has more commentary over at his blog:

"The truth is, guidelines and appropriate use criteria are used sparingly in practice. Occasionally, in a tough case. But there is such a guideline explosion, you need a guideline for the guidelines.  I don’t blame practicing clinicians when they ignore them. If we are to tackle this problem seriously, what we need of our doctors needs to be baked into their (our) daily cognitive frames, habits, and attitudes."

Take a look at the whole post--it's definitely worth a read.

We'll certainly be covering this initiative as it continues--there are another eight or more specialty societies preparing lists now, for release this fall,  including hospice and palliative care, geriatrics, and hospital medicine. Be sure to check out the website for the Avoiding Avoidable Care conference, as well (avoidablecare.org)--we'll be talking about a lot of the same issues!

Florida v. HHS, Round 2: FIGHT!

  • By
  • Joe Colucci
March 28, 2012
Publication Image

Day two of argument is posted!

Apologies for not managing to post this yesterday, but the oral argument audio from yesterday's consideration of the Miminum Coverage Provision (the individual mandate). Yesterday's Twittersphere consensus was that the argument went badly for Solicitor General Verrilli, and we have to agree--there were moments when he seemed to stumble over his arguments, and points that could have been made more clearly and forcefully. The case is far from over, though, and anything the Solicitor General missed in oral argument is surely covered in the government's briefs.

Go have a listen! Today's arguments are the last: this morning, and hour and a half on severability (whether the Court must strike down the whole law, if the individual mandate falls), and an hour this afternoon on whether the Medicaid expansion is coercive to the states. That last argument is incredibly important for the federal balance of power--Aaron Carroll has a good piece on it at the JAMA Forum blog--but it would be incredibly surprising if the Court decided to strike it down. We'll post audio this evening, when both sessions are out.

Final Round: FIGHT!

  • By
  • Joe Colucci
March 28, 2012
Publication Image

Wow. Over six hours of argument later, we're left with... well, a little over six hours of audio. Now we get to wait for the decision--only 89 days to go! (The opinion will almost certainly be issued on the last day of the term, which is scheduled for Monday, June 25th.)

We haven't had a chance to listen to today's arguments yet, so without comment: this morning, in National Federation of Independent Businesses v. Sebelius, the Court considered whether the remainder of the Affordable Care Act can stand if the Court finds the individual mandate unconstitutional. This afternoon, again in Florida v. Department of Health and Human Services, the Court heard argument about the Medicaid expansion in the law--specifically, whether it amounts to an impermissible coercion of the states by the federal government. Remember, this one is incredibly important for the federal-state balance. The Supreme Court has never struck down spending as coercive before, and it would be shocking if they did now. See Aaron Carroll's piece over at JAMA if you're interested in more.

We'll be back with more blogging soon (and probably more commentary on the arguments), but in the meantime, check out the recordings! Happy listening.

A Request

  • By
  • Joe Colucci
March 26, 2012

Hello readers,

We're working on a story about the deterioration of the doctor-patient relationship, and we're looking for your stories.If you've felt like your doctor doesn't pay attention to you, or doesn't spend enough time making sure you understand your medical needs, please send us an email! The best way to contact us is by emailing patientstales@gmail.com. We hope you'll share your story!

Issues:

Florida v. HHS, Round 1: FIGHT!

  • By
  • Joe Colucci
March 26, 2012
Publication Image

We're holding off until after the whole oral argument is finished to comment, but there's no use making you wait: the audio is posted for Day 1 of Florida v. HHS, the Supreme Court case that will(?) decide the fate of the Affordable Care Act. Today's argument was actually about the question of whether the case could be brought at all: the suit might be prevented by the 1867 Tax Anti-Injunction Act, which basically prevents lawsuits to stop collection of taxes before those taxes actually take effect. If the Court decides that the Act applies, the whole case would be thrown out, and couldn't be decided until after the mandate goes into effect in 2014--meaning we might not have a ruling on its legality until 2016.

Enjoy the audio! We'll be back tomorrow for Round 2, the main event: the oral argument over the Minimum Coverage Position, aka the individual mandate.

Avoidable Care Conference: the schedule is live!

  • By
  • Joe Colucci
March 19, 2012
Publication Image

We've been pretty quiet here at New Health Dialogue recently, but rest assured that our blogging will resume apace in the next couple of months. We've been busy working on a few projects, and I want to share one of them with you now. You'll hear more about the others soon...

If you follow our Twitter account (you should!) or Chelsea Conaboy of the Boston Globe, you've heard about the Avoiding Avoidable Care conference that we're hosting with the Lown Cardiovascular Center next month. (Chelsea did a great writeup on the conference over at the Globe's White Coat Notes blog.)

The agenda for the conference is up! We're thrilled to have such a great set of speakers, moderators, and panelists--it's going to be a great conference. While the meeting is by invitation only, we'd love to hear your comments on the agenda--post them here, and look for more in late April when we tell you about what the meeting covered.

Values and evidence: There's a difference.

  • By
  • Joe Colucci
March 12, 2012
Publication Image

In her latest column at TIME Ideas, Shannon Brownlee takes on the controversy over the Obama administration's birth control rule, and links it to some of the other purportedly moral debates over the extent of health insurance coverage. The core point is that, while each person is entitled to his own opinion, we're not entitled to our own facts. In cases where the facts line up solidly against a treatment, as with some kinds of back surgery, PSA testing for prostate cancer, and other elective procedures, it makes sense to limit the extent to which taxpayers and other members of insurance pools have to subsidize care. In cases where moral beliefs are at issue, though, we have to be careful to respect differences:

...the medical issues that are now sparking debate have relatively little to do with the pure numbers or effectiveness. The controversy arises because people have different moral beliefs. In a pluralistic society, we should try to respect and even celebrate that. When it comes to decisions that are rooted in values, I don’t want anyone—be it the government, my employer, or somebody else’s religious leader—coming between me and my doctor.

And we're back, with Health Wonk Review!

  • By
  • Joe Colucci
March 1, 2012
Alistair Cookie

Apologies for our extended hiatus--we've been hard at work on an extended report, and it hasn't left a lot of time for blogging lately. But we're back, and hopefully we'll be blogging more often in the coming weeks.

Now, without further ado: this week's Health Wonk Review is up! Check it out.

Many thanks to Joe Padua at Managed Care Matters for hosting!

Join us again on March 14th, for the next exciting edition of Health Wonk Review!

Price Transparency: Progress, Not Panacea

  • By
  • Joe Colucci
February 27, 2012
Publication Image

Shannon Brownlee's most recent TIME Ideas op-ed is up, and it tackles one of the most-repeated ideas in health care: If we give patients a financial stake in choosing less expensive care, and provide good information about which providers are cheaper than others, we'll end up with higher-value care. (After all, it works in lots of other markets--we don't have a crisis of spiraling iPad costs and lower-than-expected outcomes.) Brownlee's piece gets to the heart of why price transparency doesn't go far enough, though:

"So why do I still have no idea which lens to choose? Because I still need more information. All I know about this lens is what the slick brochure from the manufacturer is telling me. But how safe is the more expensive lens? What are the long-term effects? Can I get a new lens put in if it goes bad? That kind of information just doesn’t exist — as it doesn’t for many medical procedures."

You can read the rest of the article here: http://ideas.time.com/2012/02/27/can-you-comparison-shop-for-surgery/#ixzz1ncfvpkNU

Loss Leaders, Ahoy!

  • By
  • Joe Colucci
February 13, 2012
Publication Image

In her latest installment at TIME Ideas, Shannon Brownlee takes on hospitals that use marketing tactics like offering free screening tests to patients to generate revenue and find new recurring patients, and then claim the cost of those tests as charitable activity to become eligible for billions of dollars in tax breaks. As Brownlee points out, those tactics (minus the tax exemption part) are common across retail--and nobody accuses Amazon of being a charity:

"Hewlett Packard and other manufacturers sell computer printers at rock bottom prices. Once you run out of ink, you find out the cartridge costs almost as much as the printer did. The biggest product launch of last Christmas — Amazon’s Kindle Fire tablet — sold for less than the price of its components, even without accounting for Amazon’s advertising costs. Amazon makes it up on the e-books, TV shows, and Amazon Prime subscriptions purchased by Fire users."

You can read the full piece here: http://ideas.time.com/2012/02/13/direct-marketing-and-deep-discounts-come-to-health-care/#ixzz1mHdv3qXb

Combating "Pharmapayola"

  • By
  • Joe Colucci
January 31, 2012
Publication Image

Shannon Brownlee has a new piece up over at TIME Ideas. This time, it's a preview of the whole mess of information patients will soon be able to get about their doctors' financial relationships. It doesn't look pretty.

"As of this year, doctors who accept gifts and payments from drug and device makers will see their names on the web, the result of the 2010 Physician Payment Sunshine Act, one of the most controversial provisions in the health care reform law. Companies will be required to report any gift or payment to a doctor or academic researcher over $10, whether it’s in the form of stock options, speaking fees, box seat tickets, knickknacks for the doctor’s office or travel to a medical conference. Doctors will also be required to disclose payments and gifts."

While those payments don't necessarily meet the classic definition of payola (they are not a literal quid pro quo), the evidence showing its effect on prescribing habits is clear: Docs who take money from Pharma use their funders' products more often. Given the already-rampant misuse and ineffective use of prescription drugs and medical devices, that's ample reason to be concerned. When the data come out, check your doctor: you may be surprised.

Health Wonk Review: Look to the future edition!

  • By
  • Joe Colucci
January 19, 2012
Publication Image

Yes, folks, it's back! This week's Health Wonk Review is up, hosted by Julie Ferguson at Worker's Comp Insider.

This edition has stories on the promise of better IT for improving primary care, the Supreme Court and the ACA, scaremongering about neurosurgery for seniors, the Presidential candidates' financial relationships with health care companies, and more.

Check back on February 2nd for the next exciting edition of Health Wonk Review, hosted by Louise Norris at Colorado Long Term Care Insider!

Issues:

Mattress Graves

  • By
  • Joe Colucci
January 17, 2012
Publication Image

Shannon Brownlee's back at TIME Ideas with a new op-ed yesterday: this one about the article we mentioned last month, called How Doctors Die. Brownlee adds more context to the first commentary, by retired physician Ken Murray, with gut-wrenching descriptions of precisely why doctors tend to avoid intense, invasive care at the end of life:

"Doctors also know that undergoing heroic measures is a lousy way to die. They’ve seen what it’s like for an elderly patient to end up in the ICU, hooked up to machines, often semiparalyzed, in pain, lying on what philosopher Sidney Hook called “mattress graves” during his own terminal illness. At a recent meeting I attended, one emergency physician tearfully admitted she didn’t think she could stand to hear the sound of ribs breaking as she perform CPR on yet another elderly patient who almost certainly would not survive."

Brownlee also mentions Angelo Volandes, a physician who's working on a series of videos illustrating what it actually means to go through various heroic efforts at extending life. We think such an effort could be incredibly valuable to patients, and will help prevent a lot of unnecessary suffering, and we applaud the project.

FDA: "Intellectual" conflict of interest more serious than actual conflict

  • By
  • Joe Colucci
January 13, 2012
Publication Image

Conflict of interest is back in the news this week, with a new story in the Washington Monthly by medical journalist Jeanne Lenzer and Keith Epstein. The story, also reported on by the Wall Street Journal and co-published with BMJ, reports that three decisive votes on a recent FDA safety evaluation panel had financial relationships with Bayer--maker of the drugs in question.

Yaz, Yasmin, Beyaz, and Safyral are Bayer's birth control drugs that contain the hormone drospirenone. Such drugs have come under heavy fire in recent years for being unsafe. Consumers and researchers have argued that the drugs increase the likelihood of fatal blood clots, deep vein thrombosis, and other serious adverse events.

In light of those allegations, the FDA convened a panel to assess the evidence. Five or six members of that panel had financial relationships with Bayer; in what appears to be a violation or misapplication of the FDA's conflict of interest rules, they were still allowed to vote. That undermines the intent of conflict of interest rules, which should aim to protect public confidence in the FDA and avoid even the appearance of impropriety. In the end, all conflicted panelists voted that the drug was safe enough to stay on the market; if the their votes had switched, it would have reversed the 15-11 vote.

The truly absurd part of this story is the member the FDA chose to exclude from voting: consumer advocare Sidney Wolfe.  Wolfe had previously made statements critical of the drugs, and so the FDA deemed that he had an "intellectual conflict of interest." Such a charge is inane; if he was conflicted, surely any clinician who had ever prescribed (or declined to prescribe) one of the drugs would be similarly unable to vote! FDA panelists are responsible for doing exactly what Wolfe does: evaluating the evidence and coming to a conclusion. Making familiarity with the evidence a disqualifying factor is patently ridiculous and contrary to the purpose of the board.

One in Seven

  • By
  • Joe Colucci
January 10, 2012
Publication Image

If you ran a summer camp that never reported the vast majority of times that you hurt one of your campers, you'd probably be shut down, arrested, or worse. The situation would be similar if a restaurant repeatedly made customers sick, or if a skydiving business habitually gave people the wrong parachutes.

Why, then, do hospitals only report about one in seven of the hundreds of thousands of medical errors, infections, and other adverse events that harm patients every year? And why can they get away with it?

That's a crucial question posed by Shannon Brownlee's most recent piece on TIME Ideas: An American Hospital: The Most Dangerous Place? Brownlee addresses the recent report from the US Department of Health and Human Services, which catalogued problems with the reporting system for medical errors and other patient harm. She argues that the reporting problems are only a piece of a larger quality and safety problem, and that hospitals need to move quickly to adopt checklists and other types of safety mechanisms:

"Some hospitals have made great strides in reducing errors and infections using — you guessed it — checklists. About 10 years ago, Dr. Peter Pronovost, an intensive-care specialist at Johns Hopkins Hospital in Baltimore, and a team of colleagues put together a series of checklists for some of the most common procedures performed in the intensive-care unit. For example, they created a list of steps for how to put in a central line — a tube for delivering medication directly into a vein in the patient’s chest — in a way that reduced the risk of infection. They made a checklist to prevent patients on a ventilator, or breathing machine, from contracting pneumonia. When Pronovost was given a grant to get every ICU in the state of Michigan to use just three of his checklists, the result was 1,500 lives saved and the state of Michigan saved $100 million."

You can read the full story here: http://ideas.time.com/2012/01/09/american-hospitals-the-most-dangerous-place/

SCOTUS and the Affordable Care Act: The Countdown Begins...

  • By
  • Joe Colucci
January 9, 2012
Publication Image

Various groups, including the Attorneys General of twenty-six states, the National Federation of Independent Businesses, and several individuals, have sued the federal government over parts of the Affordable Care Act. Specifically, they've alleged that the mandate requiring individuals to purchase health insurance is unconstitutional -- it overreaches the enumerated powers of the federal government. The case was recently accepted by the Supreme Court, with oral argument scheduled for March and a decision likely by the end of June. If the Court accepts the plaintiffs' arguments, they could strike down the individual mandate (which could create huge moral hazard problems and be catastrophic for the insurance industry) or strike down the law in its entirety.

As the excitement builds for the coming arguments, Meghan McCarthy of the National Journal issued a call for opinions and predictions on the final fate of the individual mandate. Here's our take:

The final ruling on the individual mandate is tough to forecast, but we're fairly confident that the Court will not strike it down. The challenge is based on whether Congress's power to regulate interstate commerce extends far enough to allow the federal government to require all citizens to purchase health insurance or pay a penalty.

The ruling will depend in part upon how the Court sees uninsurance: is it an active choice for an individual to go bare, in effect to self-insure, or is it due to inaction? The precise definition of action and inaction is a bit murky, but here’s how the argument goes. If going without health insurance is inaction, the Court has to deal with the messy question of whether Congress can regulate inaction when it affects interstate commerce. (Throughout the case, opponents of the Commerce Clause justification for the individual mandate have asked the government just how far Congress's power stretches. Their favorite example has been the purchase of broccoli: can Congress require everyone in the country to buy broccoli? So far, the government has not said "no" -- after all, choosing to buy, or not buy broccoli affects a whole series of interstate markets for leafy green commodities. We won't weigh in on the validity of that argument, but we agree with the Cato Institute's Ilya Shapiro that the government's inability to establish a limiting principle for the Commerce Clause may prove problematic when this argument reaches the Supreme Court.

We actually don't think the case needs to address the issue of action versus inaction at all. In the case of health care and health insurance, there simply is no inactive choice. Going without health insurance is inherently different from going without broccoli, because everyone has some interaction with the health care system at some point. Even if you choose not to buy health insurance, there is a good chance that you will need health care at some point. You are in a car accident, you get brain cancer, you fall down your stairs and break your leg. Since virtually everyone will, at some point, need  health care (and must therefore have a way to pay for it), choosing to go without private or public insurance is, in fact, choosing to self-insure. Since choosing self-insurance is an action that affects interstate commerce, it's clearly within Congress's power to regulate.

Alternatively, the Court might just accept the notion that the mandate is a tax (since its only enforcement mechanism is a penalty), in which case it is unambiguously within Congressional power. That might be more palatable to Justices uncomfortable with striking down the law, but who also don't believe in the expansive Commerce Clause power that the government's position implies.

Health Wonk Review: First of 2012!

  • By
  • Joe Colucci
January 5, 2012
Publication Image

We're starting off the new year right with this election year's first Health Wonk Review!

This week, our host Jared Rhoads of the Center for Objective Health Policy has articles on Newt Gingrich, Medicare fraud (or just silly payment mechanisms), disease creep, and a smattering of year-end wrap-ups.

Issues:

Unwrapping Early Presents: It's a new Health Wonk Review!

  • By
  • Joe Colucci
December 22, 2011
Publication Image

It's that time again, folks! The Health News Watchdog hosts this week, at Gary Schweitzer's Health News Review. We've got a great collection of posts on everything from bundled payments and playtime with robot surgery to prostate cancer and informed consent.

Check it out!

Issues:

Before you cut me, cut the legalese!

  • By
  • Joe Colucci
December 15, 2011
Publication Image

Ever read a credit card agreement?

Yeah, I haven’t either.

We all know it’s important to understand the terms and conditions attached to these all-important pieces of our financial lives, but credit card agreements are long, boring and full of unintelligible boilerplate legal language. Even if we did read them, whether we'd learn anything is far from certain.

That’s why the Consumer Financial Protection Bureau (the new financial regulator born of the Dodd-Frank Act) has created a new, simplified version of a credit card agreement that is designed to provide consumers with something they can actually read before signing up for the card. The hope is that the documents will become useful tools for comparing different card offers, rather than being the thing you dig through to find out what went wrong when your rate suddenly goes up.

The Creative Commons project has used a similar system very effectively for dealing with its copyright licenses. Each CC license (there are several, allowing different levels and types of usage) is a complete contract, full of legalese and probably incomprehensible to most people. In addition, though, the contracts have “human-readable” summaries that lay out the important differences between licenses, and clearly state what people may and may not do with copyrighted material. The summary states that it isn’t the full license—it’s not a legal document -- and it doesn't lay out all the specific details that might be relevant in some cases, but for most people it's good enough.

Anyone who's ever had surgery, or even a colonoscopy, knows that the legal paperwork in medicine is just as dense as it is in banking--and the stakes are much higher. Given that, it seems like there should be a huge movement in the medical community toward creating human-readable paperwork for patients. The current system is clearly failing: people sign the documents, but the ideal of informed consent is being left behind. In too many cases, patients give consent--but they aren't informed. 

The real goal of the new credit card agreement is not only to disclose the terms of use, but to help customers make active choices among their credit options. Patient decision aids (which we've written about before) are a crucial tool for doing that in a medical setting. There's a huge opportunity to make patients much better off by giving them information that they can use to make decisions. Here's hoping  health care agencies will follow the CFPB's lead, and push hard for patients to have understandable and comparable information about their treatment (and non-treatment) options.

Issues:

The End of Blockbuster Drugs?

  • By
  • Joe Colucci
December 13, 2011
Publication Image

The expiration of Pfizer's patent on atorvastatin--the chemical behind the blockbuster cholesterol-lowering pill Lipitor--marks a potentially transformative moment for the drug industry. Currently the best-selling drug in the world, Lipitor (and soon several of its fellows) will have to compete with cheaper generics for market share, putting pressure on drug companies to come up with the next round of blockbusters.

We hope that doesn't happen--and in her column over at TIME Ideas, Shannon Brownlee has some comments on why. Basically, the structure of the pharmaceutical industry pushes doctors toward prescribing and patients toward taking lots of pills that we don't really need. That's driving Here's her commentary on what might change to mitigate that pattern in the future:

"...even while Pfizer is now attempting to hold on to its market share by cutting deals with pharmacy benefits managers and directly targeting patients, there are several possible solutions to the blockbuster problem, some of which will happen all on their own. Genomics research will clarify who can really benefit from which drugs and who won’t be helped at all and will make it harder and harder to sell a pill to everyone. Through efforts like the National Physicians Alliance’s Top 5 project, doctors will become even more aware of marketing tactics and will be motivated to stop doing things that don’t benefit patients.Some experts have suggested changing patent law to give drug companies a set amount, say 15 years, of market exclusivity starting from the time they bring the drug to market. (Under current patent law, the clock starts ticking when the patent on the molecule is filed but development might take longer.) This might discourage the legal maneuvering they now engage in (tinkering slightly with the formula, etc.) to delay the moment when generics come in. I think it would be more effective to outlaw, or at least curtail, direct-to-consumer drug advertising, which has contributed mightily to the industry’s success in selling sometimes inappropriate drugs to patients."

You can read the full column here. We'll continue to cover any interesting developments in the blockbuster drug saga--to stay on top of all our posts, don't forget to follow us on Twitter!

Health Wonk Review: Holiday Shopping Guide Edition!

  • By
  • Joe Colucci
December 8, 2011
Publication Image

This week's Health Wonk Review is so good, I'm not going to even try to summarize it. Ladies and gents, I give you the Holiday Shopping Guide!

Thanks to Brad Wright for hosting, and check back with us in two weeks when Gery Schweitzer hosts at Health News Review!

Issues:
Syndicate content